NY-ORIGINS
14.10.2020 15:08:08 CEST | Business Wire | Press release
Origins, a prestige global skincare brand that delivers high-performance formulas powered by nature and proven by science, and its parent company, The Estée Lauder Companies (ELC), today announced a partnership with global chemical industry leader SABIC and strategic beauty packaging manufacturer Albéa to bring an advanced recycled tube package to market in 2021.
Origins will be the first prestige beauty brand to leverage SABIC’s innovative, advanced recycling technology to produce a tube pack format made from previously difficult to recycle, post-consumer mixed plastics material.
Launching with Origins global best-selling mask, Clear Improvement™ Active Charcoal Mask will be packaged in a tube composed of a circular polymer resin made using SABIC’s revolutionary, certified circular polyethylene and polypropylene advanced recycling technology. As a pioneer in the development of sustainable packaging for beauty brands, Albéa will leverage its expertise in the use of recycled resins to deliver a high-performing tube experience.
Traditional recycling streams for plastics are limited, and plastics can only be recycled a finite amount of times. Advanced recycling returns hard-to-recycle plastics, otherwise destined for incineration or landfill, back to their basic building blocks. Once the plastic has been broken down to its molecular state, it is then used to create high-performance plastics akin to a virgin material. SABIC’s ground-breaking, certified circular polymer, part of its TRUCIRCLE™ portfolio of circular solutions, uses this technology which is capable of continually converting plastics back to the original polymer. Through the use of this innovative recycling technology, Origins, ELC, SABIC and Albéa are helping to drive innovation across the value chain toward the goal of a circular plastic economy.
This strategic partnership aligns with ELC’s sustainable packaging goals, which includes increasing the amount of post-consumer recycled (PCR) material in its packaging by up to 50% by 2025, and will further Origins efforts to ensure that at least 80% of the brand’s packaging by weight is recyclable, refillable, reusable, recycled or recoverable by 2023.
SABIC's certified polymers are based on a mass balance approach. To secure the chain of custody, the value chain parties require an ISCC PLUS certification. This widely recognized international sustainability certification scheme verifies that the mass balance accounting follows predefined and transparent rules. In addition, it provides traceability along the supply chain, from the feedstock to the final product.
“Respect for the well-being of your skin and our planet is ingrained into our brand’s DNA. It guides our actions and is reflected in our Origins offerings which is why we’re excited to partner with SABIC and Albéa to provide our consumers with a safe, high-quality and responsible packaging solution that helps reduce our impact on the environment,” says Francesca Damato, Origins Vice President Global Marketing and Product Development. “Together, we have an exciting opportunity to define how the prestige beauty industry can create sustainable, attractive packaging solutions that please both consumer and the planet. This is a significant first step in the transition towards a circular economy, helping to close the loop on plastic waste.”
“At The Estée Lauder Companies, we approach sustainable design options for our prestige and luxury packaging with a spirit of collaboration. To further our focus on reducing the potential environmental impacts of a package across its lifecycle, we are proud to partner with SABIC and Albéa on Origins industry-first sustainable packaging innovation,” said Sushil Iyer, Vice President, Global Packaging, The Estée Lauder Companies. “Exploring the uses of advanced recycled PCR has incredible potential to help drive the achievement of our sustainable packaging goals, and we are excited to bring this product to market.”
Mark Vester, Circular Economy Leader at SABIC, said “The new Origins packaging is the result of true collaboration and innovation, and another step closer to closing the loop on used plastics. We are committed to collaborating with partners across the value chain to work towards a more sustainable, circular future.”
“Albéa has been at the forefront of sustainable development in packaging for many years and was the first beauty packaging company to commit to making their solutions 100% circular by 2025. This breakthrough with Origins, The Estée Lauder Companies and SABIC is an industry first – paving the way for the use of advanced recycled, post-consumer waste into prestige beauty packaging thanks to an innovative source of high-quality resins,” says Stéphane Barlet, VP of Sales, Albéa Americas. “This co-development also highlights the importance of partnership and audacity across the value-chain, which is crucial to accelerate the transition to recyclable and reusable packaging."
About Origins
Prestige global skincare brand, Origins combines high-quality plant, earth and sea-based ingredients with non-toxic-to-skin alternatives and advanced science to create safe, high-performance products that deliver transformative results. Since inception in 1990, Origins has been committed to respecting the well-being of your skin and our planet – from traveling the world to discover nature’s potent ingredients to endeavoring to make choices that help reduce our impact on the planet. The brand formulates without: parabens, phthalates, propylene glycol, formaldehyde, sodium lauryl sulfate (SLS), mineral oil, petrolatum, paraffin, diathanolamine (DEA), polyethylene beads and animal ingredients (except cruelty free honey & beeswax). Origins is available in 30 countries. For more information, visit www.origins.com ; never stop discovering™ and follow @Origins .
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.
About SABIC
SABIC is a global leader in diversified chemicals and the company manufacture on a global scale in the Americas, Europe, Middle East and Asia Pacific, making distinctly different kinds of products: chemicals, commodity and high performance plastics, agri-nutrients and metals.
At SABIC, we are working to drive the change needed to close the loop on used plastic. This includes SABIC’s TRUCIRCLE™ portfolio and services which showcases our circular innovations, including our certified circular products which are produced using a feedstock derived from previously difficult to recycle used plastic household packaging. We are collaborating with retailers, recyclers and manufacturers to close the loop and to accelerate the changes we need to make to become a circular global society.
SABIC has more than 33,000 employees worldwide and operates in around 50 countries. Fostering innovation and a spirit of ingenuity, we have 12,540 global patent filings, and have significant research resources with innovation hubs in five key geographies – USA, Europe, Middle East, South Asia and North Asia.
Visit our website for more information: www.sabic.com .
About Albéa
We invent and make responsible packaging – tubes, lipsticks, mascaras, fragrance caps, skincare jars and turnkey solutions – for the beauty, personal care and health markets. Yet we believe there can be no responsible packaging without a responsible company. That’s why we uphold the reputation of our dynamic and prestigious customers; we act for the environment; we support our communities; we invest in technical expertise and world-class equipment for our 32 modern facilities worldwide; and we care for our 12,000 talented people. At Albéa, we protect Beauty. www.albea-group.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005567/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
